Steven Cohen's FOLD Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 7.16 M shares of Amicus Therapeutics, Inc. (FOLD) worth $56.39 M, representing 0.09% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 37 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in FOLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 4.75 M shares. Largest reduction occurred in Q3 2023, reducing 6.05 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +195,900 | New Buy | 195,900 | $5.95 |
| Q4 2014 | -195,900 | Sold Out | 0 | $0.00 |
| Q1 2015 | +173,900 | New Buy | 173,900 | $10.88 |
| Q2 2015 | +742,800 | Add 427.14% | 916,700 | $14.15 |
| Q3 2015 | -916,700 | Sold Out | 0 | $0.00 |
| Q1 2017 | +3 M | New Buy | 3 M | $7.13 |
| Q2 2017 | -1.13 M | Reduce 37.57% | 1.87 M | $10.07 |
| Q3 2017 | -133,654 | Reduce 7.14% | 1.74 M | $15.08 |
| Q4 2017 | +1.13 M | Add 65.00% | 2.87 M | $14.39 |
| Q1 2018 | -2.87 M | Sold Out | 0 | $0.00 |
| Q2 2018 | +707,300 | New Buy | 707,300 | $15.62 |
| Q3 2018 | +1.62 M | Add 229.31% | 2.33 M | $12.09 |
| Q4 2018 | +1.47 M | Add 63.17% | 3.8 M | $9.58 |
| Q1 2019 | -3.8 M | Sold Out | 0 | $0.00 |
| Q2 2019 | +3.03 M | New Buy | 3.03 M | $12.48 |
| Q3 2019 | -1.76 M | Reduce 58.12% | 1.27 M | $8.02 |
| Q4 2019 | -1.27 M | Sold Out | 0 | $0.00 |
| Q1 2020 | +2.24 M | New Buy | 2.24 M | $9.24 |
| Q2 2020 | -1.22 M | Reduce 54.59% | 1.02 M | $15.08 |
| Q3 2020 | +522,513 | Add 51.30% | 1.54 M | $14.12 |
| Q4 2020 | -1.54 M | Sold Out | 0 | $0.00 |
| Q1 2021 | +177,322 | New Buy | 177,322 | $9.88 |
| Q2 2021 | +3.69 M | Add 2081.00% | 3.87 M | $9.64 |
| Q3 2021 | -3.87 M | Sold Out | 0 | $0.00 |
| Q1 2022 | +475,500 | New Buy | 475,500 | $9.47 |
| Q2 2022 | +642,400 | Add 135.10% | 1.12 M | $10.74 |
| Q3 2022 | +528,500 | Add 47.28% | 1.65 M | $10.44 |
| Q4 2022 | -1.65 M | Sold Out | 0 | $0.00 |
| Q1 2023 | +2.25 M | New Buy | 2.25 M | $11.09 |
| Q2 2023 | +4.75 M | Add 211.27% | 7 M | $12.56 |
| Q3 2023 | -6.05 M | Reduce 86.48% | 946,697 | $12.16 |
| Q4 2023 | -946,697 | Sold Out | 0 | $0.00 |
| Q3 2024 | +1.27 M | New Buy | 1.27 M | $10.68 |
| Q4 2024 | -1.27 M | Sold Out | 0 | $0.00 |
| Q1 2025 | +2.99 M | New Buy | 2.99 M | $8.16 |
| Q2 2025 | +293,939 | Add 9.85% | 3.28 M | $5.73 |
| Q3 2025 | +3.88 M | Add 118.25% | 7.16 M | $7.88 |
Steven Cohen's Amicus Therapeutics Investment FAQs
Steven Cohen first purchased Amicus Therapeutics, Inc. (FOLD) in Q3 2014, acquiring 195,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Amicus Therapeutics, Inc. (FOLD) for 37 quarters since Q3 2014.
Steven Cohen's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q2 2023, adding 7,000,900 shares worth $87.93 M.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 7,156,557 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $56.39 M.
As of the Q3 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.09% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Amicus Therapeutics, Inc. (FOLD) was 7,156,557 shares, as reported at the end of Q3 2025.